Equinor sells the Peregrino field for USD 3.5 billion GlobeNewswire May 02, 2025 Equinor Brasil Energia Ltda., a subsidiary of Equinor (OSE: EQNR, NYSE: EQNR), has entered into agreements(1) with Brazilian company Prio Tigris Ltda., a subsidiary of PRIO SA (PRIO3.SA) for a sale of its 60% operated interest in the Peregrino field in Brazil. […]
Flow Force Max Under Review: Natural Chewable Candy Ingredients to Support Prostate Health for Men Clinically-Inspired 3-Phase Formula Combines Graminex Flower Pollen, Saw Palmetto & Muira Puama to Help Men Over 40 Regain Prostate Comfort, Energy & Confidence–Now Backed by 60-Day Guarantee. GlobeNewswire May 02, 2025 New York, May 01, 2025 (GLOBE NEWSWIRE) — In
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In enCore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in enCore between March 28, 2024 and March 2, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi
Fluxactive Under Review: The Complete Prostate Wellness Formula for Bladder Support Discover How Fluxactive Complete Supports Prostate Health, Enhances Urinary Flow, and Restores Confidence Naturally–With Honest Reviews, Full Ingredient Insights, and a Clear Guide to Results. GlobeNewswire May 02, 2025 New York, May 01, 2025 (GLOBE NEWSWIRE) — In This Article, You'll Discover: What Fluxactive
EyeFortin Under Review: Powerful Vision Supporting Formula for Optimal Eyesight Health Discover how EyeFortin's liquid formula harnesses amino acids, plant extracts, and neuro-visual nutrients to rebuild the eye-brain connection, reduce digital eye strain, and restore sharper, clearer vision–backed by real user results and a 60-day risk-free guarantee. GlobeNewswire May 02, 2025 New York, May 01,
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Actinium between October 31, 2022 and August 2, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In NET Power To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in NET Power between June 9, 2023 and March 7, 2025 and would like to discuss your legal rights, call Faruqi
(Copenhagen:GMAB),(LSE:0MGB), Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE(R) FL-1 trial Full results from the trial will be submitted for presentation at an upcoming medical conference in 2025 COPENHAGEN, Denmark; May 2, 2024 – Genmab A/S
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) GlobeNewswire May 02, 2025 Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in